Johnson & Johnson’s Spravato Offers Hope for Treatment-Resistant Depression
Nearly 21 million adults in the United States experience clinical depression or major depressive disorder. For many, traditional treatments such…
Nearly 21 million adults in the United States experience clinical depression or major depressive disorder. For many, traditional treatments such…
Governor Kathy Hochul announced the launch of Mental Health Awareness Month with a significant update on New York’s mental health…
Yong Chen, a senior fellow at the Leonard Davis Institute (LDI) and a professor at Penn Medicine, has been awarded…
Academics at the University of Portsmouth are conducting a groundbreaking study to explore whether cold water swimming can help alleviate…
Researchers at the University of Portsmouth are conducting a study to see if cold water swimming can alleviate symptoms of…
Starting May 1, 2025, Australians suffering from treatment-resistant depression will gain access to Spravato (esketamine), a new nasal spray treatment…
Post-stroke depression (PSD) affects approximately 30% of stroke survivors, leading to reduced recovery outcomes, cognitive impairments, and diminished quality of…
Beginning May 1, 2025, Australians suffering from treatment-resistant depression will have access to a new medication, esketamine, under the Pharmaceutical…
A new nasal spray using a form of ketamine will soon be available to treat severe depression in Australia, as…
A new study from the University of Arizona (U of A) and Radboud University in the Netherlands introduces a precision…